Developing new chemical tools for cancer treatment
Chemical Probes and Drug Discovery
This study is exploring new ways to create drugs that can help fight cancer by breaking down a specific protein linked to the disease, aiming to find better treatments for patients.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wistar Institute NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11085170 on NIH RePORTER |
What this research studies
This research focuses on creating innovative chemical probes and drug candidates aimed at degrading specific proteins involved in cancer progression, particularly targeting the EBNA1 protein associated with certain cancers. The team will utilize advanced techniques in assay development and synthetic chemistry to screen and develop these new compounds. By comparing the effects of protein degradation versus traditional inhibition methods, the research aims to identify more effective treatments for cancer patients. The approach includes using small DNA oligos and E3 ligase recruiting molecules to enhance the efficacy of the drug candidates.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers associated with the EBNA1 protein or those who may benefit from novel anti-cancer agents.
Not a fit: Patients with cancers not related to the EBNA1 protein or those who do not respond to targeted therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that specifically target and degrade harmful proteins, potentially improving patient outcomes.
How similar studies have performed: Other research has shown promise in using targeted protein degradation as a therapeutic strategy, indicating that this approach could be a significant advancement in cancer treatment.
Where this research is happening
Philadelphia, United States
- Wistar Institute — Philadelphia, United States (Active)
Researchers
- Principal investigator: Salvino, Joseph M — Wistar Institute
- Study coordinator: Salvino, Joseph M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.